Table 1.
Patient Characteristics of Our Study
| Overall (N = 271) | Single Switch (N = 101) | Double Switch (N = 170) | P | ||
|---|---|---|---|---|---|
| Age (mean ± SD) | 53.00 ± 16.66 | 52.30 ± 15.72 | 53.41 ± 17.23 | 0.595 | |
| Gender | Male | 248 (92) | 96 (95) | 152 (89) | 0.107 |
| Female | 23 (8) | 5 (5) | 18 (11) | ||
| Race | Caucasian | 226 (83) | 86 (85) | 140 (82) | 0.045 |
| African American | 27 (10) | 11 (11) | 16 (9) | ||
| Others | 14 (5) | 1 (1) | 13 (8) | ||
| Unknown | 4 (1) | 3 (3) | 1 (1) | ||
| IBD type | CD | 149 (55) | 58 (57) | 91 (54) | 0.533 |
| UC | 122 (45) | 43 (43) | 79 (46) | ||
| Basal Metabolic Index (mean ± SD) | 29.55 ± 5.33 | 30.40 ± 5.46 | 29.03 ± 5.20 | 0.036 | |
| Disease duration (mean ± SD) | 13.20 ± 10.34 | 12.59 ± 10.03 | 13.57 ± 10.52 | 0.451 | |
| CCI* (mean ± SD) | 0.66 ± 1.26 | 0.59 ± 1.01 | 0.69 ± 1.38 | 0.528 | |
| Smoking status | Nonsmoker | 177 (65) | 66 (65) | 111 (65) | 0.892 |
| Active smoker | 40 (15) | 16 (16) | 24 (14) | ||
| Prior smoker | 54 (20) | 19 (19) | 35 (21) | ||
| 5-ASA† use | Yes | 38 (14) | 14 (14) | 24 (14) | 0.953 |
| No | 233 (86) | 87 (86) | 146 (86) | ||
| Combination therapy | Yes | 65 (24) | 30 (30) | 35 (21) | 0.089 |
| No | 206 (76) | 71 (70) | 135 (79) | ||
| Primary outcome | Yes | 71 (26) | 25 (25) | 46 (27) | 0.676 |
| No | 200 (74) | 76 (75) | 124 (73) |
*Charlson Comorbidity Index.
†Amino salicylic acid.